Law Professor Says Valeant / Ackman Model For Acquisitions Is Dead – ValueWalk Premium
Valeant Pharmaceuticals earnings

Law Professor Says Valeant / Ackman Model For Acquisitions Is Dead

The much discussed Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) / Pershing Square model for bidder / activist collaboration is dead, according to an article posted on the Harvard University Law School blog.

The article, posted by Philip Richter*, a guest contributor on the Harvard Law School’s Corporate Governance and Financial regulation blog, an Adjunct Professor of Law at New York University and a senior counsel at the law firm of Fried Frank, Harris, Shriver & . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk

0